HPTN 083-A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men (ViiV)


Total Award Amount

  • 2482280.00
  • Direct Costs

  • 1684326.00
  • Sponsor Award Id

  • PO17001904
  • Contributor

  • Edgar Overton   Principal Investigator  
  • Michael Saag M.D.   Investigator  
  • Paul Goepfert M.D.   Investigator  
  • Sonya Heath   Investigator